Skip to main content

Table 1 Availability of anti-malarials and malaria testing among all screened public sector outlets

From: The malaria testing and treatment landscape in mainland Tanzania, 2016

  Public health facility % CI Private not for-profit facility % CI Public sector total % CI
N = 341 N = 65 N = 406
Any anti-malarial 96.2 (89.0, 98.8) 96.4 (79.5, 99.5) 96.2 (90.0, 98.6)
QA ACT 92.0 (84.0, 96.2) 65.8 (49.0, 79.4) 89.1 (82.5, 93.5)
non-QA ACT 13.3 (7.5, 22.5) 29.8 (17.1, 46.7) 15.1 (9.3, 23.6)
SP 51.5 (40.3, 62.6) 54.1 (36.9, 70.4) 51.8 (41.5, 61.9)
Oral Quinine 4.6 (1.8, 11.3) 51.4 (33.9, 68.6) 9.7 (6.3, 14.6)
Other non-artemisinin therapy (amodiaquine and parenteral quinine) 9.7 (6.5, 14.2) 9.3 (3.7, 21.4) 9.7 (6.7, 13.9)
Artesunate injection 71.4 (62.9, 78.5) 24.9 (16.0, 36.6) 66.3 (57.8, 73.8)
Any malaria testing 91.8 (85.6, 95.4) 97.1 (80.6, 99.6) 92.3 (86.7, 95.7)
Malaria microscopy 18.9 (13.3, 26.2) 68.9 (54.1, 80.6) 24.3 (18.2, 31.8)
RDTs 89.3 (82.2, 93.7) 89.3 (77.4, 95.3) 89.3 (82.9, 93.4)
QA ACT and any malaria testing 86.0 (77.9, 91.5) 62.9 (46.4, 76.8) 83.5 (76.4, 88.8)
QA ACT no malaria testing 5.9 (2.8, 12.1) 2.9 (0.4, 19.4) 5.6 (2.7, 11.2)